ea0014oc8.2 | Neuroendocrinology clinical | ECE2007
De Martino Maria Cristina
, Auriemma Renata S
, Brevetti Gregorio
, Galdiero Mariano
, De Leo Monica
, Lombardi Gaetano
, Colao Annamaria
, Pivonello Rosario
Acromegaly is known to be associated to an increased cardiovascular risk, due to the increased prevalence of glucose intolerance and dyslipidemia and pre-atherosclerotic lesions. The aim of this study was to evaluate the effect of treatment with the GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in patients with acromegaly resistant to somatostatin analogues. Twelve patients (4 m, 8 f, 2858 yrs) and 24 sex-, age- and BMI-matched controls en...